Zhou et al. [21] found that 30% of COVID-19 patients have shortened prothrombin times, and coagulation dysfunction can lead to thrombosis on the surface of intravenous plaques and induce venous thrombosis, myocardial infarction, and other cardiovascular diseases. This evidence concerns the gene F2 and COVID-19.